WO2006041159A1 - プロモーター領域を付加したプライマー - Google Patents
プロモーター領域を付加したプライマー Download PDFInfo
- Publication number
- WO2006041159A1 WO2006041159A1 PCT/JP2005/018960 JP2005018960W WO2006041159A1 WO 2006041159 A1 WO2006041159 A1 WO 2006041159A1 JP 2005018960 W JP2005018960 W JP 2005018960W WO 2006041159 A1 WO2006041159 A1 WO 2006041159A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- primer
- rna
- ivt
- arna
- cycle
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6865—Promoter-based amplification, e.g. nucleic acid sequence amplification [NASBA], self-sustained sequence replication [3SR] or transcription-based amplification system [TAS]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1096—Processes for the isolation, preparation or purification of DNA or RNA cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
Definitions
- the present invention relates to a primer to which a promoter region is added. More specifically, the present invention relates to a random primer added with a promoter region and a primer containing a base sequence complementary to a specific gene added with a promoter region. The present invention also relates to a method of using these primers for RNA amplification, biological gene expression analysis and Z or identification analysis.
- RNA that can obtain tissue / cell force is used as a sample.
- RNA that can obtain tissue / cell force.
- the total RNA of pathogenic microorganisms obtained from patient-derived samples is extremely small, it is not quantitatively sufficient for analysis using microarrays or Northern blotting that require total RNA in the order of ⁇ g. It was.
- RNA after culturing and growing the collected microorganism, but depending on the culture conditions at that time and the growth time of the cell during RNA extraction, the pathogenic gene From the analysis results obtained, it is not possible to grasp the pathogenicity of pathogenic microorganisms in vivo. Therefore, in order to analyze the pathogenicity of pathogenic microorganisms, it is desired to establish a method for efficiently linearly amplifying a trace amount of pathogenic microorganism RNA that can be collected clinically.
- RNA amplification in eukaryotes is generally performed by the IVT method (In Vitro Transcription method). Since eukaryotes have a polyA structure at the end of the mRNA that is the target of gene expression analysis, a primer with a T7 promoter sequence attached to a repeating structure of thymine (T) bases is attached to this structure, and the IVT method is used. By doing so, a large amount of mRNA can be amplified from a very small amount of sample.
- IVT method In Vitro Transcription method
- RNA cannot be amplified in the same manner as in the eukaryotes.
- Prokaryotic gene amplification uses a prokaryotic RNA as a saddle type and detects RNA information by amplification using random primers or primers containing a base sequence complementary to the gene to be amplified. It is common.
- a method has also been developed in which poly-A polymerase is added to a prokaryotic RNA fragment and a polyA structure is added to bind the repeating structure of thymine (T) base as a primer to perform RT-PCR. (For example, refer to Patent Document 1).
- Patent Document 1 JP 2004-180561 A
- An object of the present invention is to provide a primer capable of stably amplifying RNA and a method for amplifying RNA using the primer. Then, it is an object to provide a method for using these primers for RNA amplification, gene expression analysis and Z or identification analysis of organisms. Means for solving the problem
- T 7 Random primers with a promoter region such as T3 or SP6, and primers containing a base sequence complementary to a specific gene with these promoter motor regions added, and using these primers As a result, the present invention was completed.
- the random primer added with the promoter region of the present invention amplifies RNA by binding the random primer region to the RNA in the form of a RNA and binding RNA polymerase to the promoter motor region after double-stranded DNA synthesis. Is possible.
- a primer region containing a complementary base sequence binds to a specific prokaryotic gene, resulting in double-stranded DNA synthesis.
- Prokaryotic RNA can be amplified by binding RNA polymerase to the promoter region.
- the present invention relates to the following (1) to (7).
- a primer characterized by adding a promoter region to a random primer
- a primer characterized by having a promoter region attached to a primer comprising a base sequence complementary to a specific gene.
- Method for amplifying RNA The method according to (5) or (6), which is an IVT method.
- the antisense aRNA (amplified RNA) obtained by the 1-cycle IVT method is further subjected to the IVT method using any of the primers described in (1) to (4) above, so that the sense aRNA is obtained.
- the primer attached with the promoter region of the present invention can amplify DNA or RNA using a very small amount of total RNA as a sample. Furthermore, it is a highly versatile primer that can amplify the mRNA of the target gene. DNA or RNA amplified by the primer of the present invention can be analyzed by microarray, Northern blot, or the like. Therefore, by amplifying RNA using the primer of the present invention, the pathogenicity of the pathogenic microorganism at the time of sampling can be analyzed.
- the "primer added with a promoter region" of the present invention means that RNA polymerase can bind to a random primer or a primer containing a base sequence complementary to a specific gene in order to amplify a truncated RNA.
- a primer with a promoter sequence added is a primer capable of amplifying the RNA to be amplified or a specific gene thereof, a misaligned one may be used, for example, by a synthesis company such as Proligo Japan. Use the synthesized primer.
- the primer of the present invention can be synthesized according to the phosphoramidide method. This person In this method, synthesis proceeds from the 3 'end to the 5' end, so a random primer region or a primer region containing a base sequence complementary to a specific gene is created, and then a promoter region is created.
- the primer of the present invention is synthesized. These synthesized primers can be purified by high performance liquid chromatography (HPLC) or the like.
- primers attached with the promoter region of the present invention the following are examples of random primers having a random primer region consisting of 9 bases and a T7 promoter region added to the terminal side. 3,
- the "promoter region” of the present invention refers to a region comprising a promoter base sequence to which RNA polymerase can bind in the amplification of RNA.
- the promoter include ⁇ 7 promoter, ⁇ 3 promoter, SP6 promoter and the like. Any of these promoter motors should be a promoter to which RNA polymerase can bind. The most stable amplification can be obtained.
- the "random primer” of the present invention refers to a primer comprising a base sequence randomly arranged in four basic strengths: adenine ( ⁇ ), thymine ( ⁇ ), glycine (G), and cytosine (C). Any primer can be used as long as it can bind to the RNA to be amplified.
- the random primer of the present invention can be prepared by a synthesizer or the like, and “a method of sequentially performing a coupling end force using a mixed amidite of A, T, G, and C” or “simultaneously A, T, It can be prepared by either the method of flowing G and C to the reaction phase or the method of flowing sequentially.
- primer comprising a base sequence complementary to a specific gene means that a specific gene is expressed! /, Complementary to the base sequence of mRNA or a specific gene. Any primer can be used as long as it is a primer to be obtained.
- the “specific gene” refers to a specific gene to be amplified for use in gene expression analysis and / or identification analysis of an organism. Specifically, it can be used for gene expression analysis and Z or identification analysis of target organisms, such as specific pathogenic genes of pathogenic microorganisms, 16S rRNA for identifying pathogenic microorganisms, etc. In these analyses, if the base sequence of the gene is very strong, a misaligned one can be used. It does not include primers with a thymine (T) base repeat structure and a T7 promoter sequence that can comprehensively amplify eukaryotic mRNA.
- T thymine
- a primer containing a base sequence complementary to a specific gene of the present invention can be prepared with a synthesizer or the like, and a necessary base sequence can be selected from the base sequence of the gene to be amplified.
- a synthesizer or the like By “A, T, G, C sequentially flowing to the reaction phase”, a single base sequence can be prepared.
- the setting of the “base sequence complementary to a specific gene” in the primer of the present invention selects a region that is specific to the gene to be amplified and has no homology with other genes. Can be set. Whether the selected region is specific to the gene can be comprehensively determined using gene sequence search software, BLAST search, or the like.
- the primer of design leave the horse chestnut child using the primer design site such as prim e r3.
- the “amplification” of the present invention refers to amplifying a truncated RNA by SMART method or IVT method, etc. using RNA as a truncated form and using a primer to which the promoter region of the present invention is added.
- Book The amplification of the invention is as follows: 1. After obtaining cDNA by RT reaction using RNA as a template, 2. Obtaining double-stranded cDNA by an existing method, 3.
- SMART primer and the present invention Amplify the region sandwiched between the primers with the promoter region by PCR (SMA RT method), or amplify RNA by binding RNA polymerase to the promoter region added to the primer of the present invention (IVT method) This can be done by steps 1 to 3.
- RNA that is easily degraded by the primer of the present invention is immediately converted to stable DNA, and therefore, there is a low possibility of RNA degradation. Therefore, even when a very small amount of RNA that is difficult to collect is used as a sample, it can be stably amplified.
- the primer with the promoter region of the present invention attached in the step 1 above is used, and the RNA is single-stranded from the RNA by RT enzyme.
- the RT enzyme used added a nucleotide residue (C) to the 3 'end of the cDNA, and the complementary oligo (G) sequence was added to the 3' end at the step 2 above.
- C nucleotide residue
- G complementary oligo
- the double-stranded cDNA can be used as a trapezoidal shape to exponentially amplify the region sandwiched between the primer with the promoter region added and the SMART primer.
- Antisense aRNA amplified RNA
- the SMART method can be performed using an existing kit, such as BD Atlas SMART Fluorescent Probe Amplification Kit (BD Bioscience), ART mRNA Amnli. Fication Kit (Clontech) or BD Atlas SMART cDNA Probe Ampli fication Kit (BD Biosciences Clontech) can be used.
- the BD Atlas SMART cDNA Probe Amplification Kit (BD Biosciences Clontec) provides results comparable to probes made from pure mRNA, even for very small amounts of RNA material (see references 2, 3 etc.) ).
- RNA when RNA is amplified by the IVT method using the primer of the present invention, a single-strand is obtained by RT enzyme using a primer in which the RNA of the present invention is attached in the step 1.
- the cDNA is synthesized, and the RNA that has been converted into a ribonuclease by RNaseH in the above step 2 is decomposed.
- double-stranded cDNA is synthesized by DNA polymerase I and T4 DNA polymerase, and the double-stranded DNA synthesized in the above step 3.
- dNTP Mix and T7 polymerase enzyme are added to cDNA and translated in vitro to synthesize and amplify antisense aRNA.
- the IVT method can be performed using an existing kit, such as MessageAmp aRNA Kit (Ambion), RNA Transcript Labeling Kit (Affymetrix), MEGAspript T7 Kit (Ambion) or MEG Aspript SP6 Kit (Ambion) Etc. can be used.
- a double-stranded cDNA is synthesized by using a primer with RNA as a saddle and a promoter region of the present invention, and amplified aRNA by the IVT method. Then, in the second cycle, reverse transcription reaction was performed using the antisense aRNA amplified in the first cycle and the promoter region of the present invention was added. After degrading the RNA, a commercially available random primer was added.
- primers used in the first and second cycles can be primers that have the same promoter region. Chains may be synthesized.
- the purified double-stranded cDNA is purified by a purification column in the Amino Allyl Message Amp aRNA Kit (Ambion), in addition to the conventionally known phenol's Kuroguchi form method. Or a purification column such as QIAquick PCR Purification Kit (Qiagen).
- RNAs Since the amplification of these RNAs is generally not affected by the concentration of each template (template) in the mixed sample or the sequence of the template in transcription, refer to References 5, 6 etc. ) All RNAs can be amplified almost linearly without depending on the individual mRNA base sequences in the mixed sample.
- RNA + mRNA can be amplified. Therefore, amplification of this RNA depends on the purpose. For example, when rRNA is not required for gene expression analysis of organisms, the RNA strength of the sample is also removed after removal of rRNA using a research kit (MICROB Express Bacterial mRNA Purification Kit: Am bion). Only the mRNA can be amplified by the primer of the invention. In addition, 16S rRNA can be amplified in the identification analysis of organisms, and by combining these, gene expression analysis and identification analysis of organisms can be performed simultaneously.
- MICROB Express Bacterial mRNA Purification Kit Am bion
- a primer containing a base sequence complementary to the specific gene is designed and a promoter region is added to the specific gene. It is also possible to analyze the expression of.
- the "gene expression analysis and Z or identification analysis of an organism" of the present invention refers to a random primer to which a promoter region of the present invention is added or a base sequence complementary to a specific gene to which a promoter region is added. This refers to analyzing the expression of microbial pathogenic genes or identifying the organism from 16S rRNA by using microarrays or Northern plots, etc., using RNA amplified with the included primers.
- aRNA amplified by the IVT method, aDNA amplified by the SMART method (amplified DNA), or transcribed cDNA should be used in the present invention for gene expression analysis and Z or identification analysis of organisms. Can do.
- RNA is more preferable for binding to a DNA probe comprising a PCR product or a synthetic oligonucleotide on a microarray because RNA is stronger than DNA.
- aRNA amplified by two consecutive IVT methods and a sense aRNA of the same copy number as a detection sample, double-stranded DNA probes such as PCR products can be spotted. ! /, The microarray can further improve the detection sensitivity.
- a double-stranded DNA-labeled probe of a specific gene is usually used by the PCR method, so both sense aRNA and antisense aRNA are simultaneously amplified and transferred to a membrane.
- the present invention are shown below, but the present invention is not limited by these.
- N6-T7primer or N9-T7primer a random primer with a promoter region attached was designed and prepared by a synthesizer (Proligo Japan).
- N6-T7primer is shown in SEQ ID NO: 1 and N9-T7primer is shown in SEQ ID NO: 2, respectively.
- Porphyromonas gineivalis strain W83 (ATCC No. BAA-308) purchased from ATCC (American Type Culture Collection; 0.5% yeast extract, L-cysteine-HC1, hemin and menadi in BHI (Brain Heart Infion) medium Cultivated in a medium supplemented with on until the mid-log phase in an anaerobic device, collected the cells, and immediately collected the Trizol solution (invitrogen), and the cell disrupter (FastPre p , BIO101) The water layer obtained by centrifugation was purified with phenol chloroform, ethanol precipitated, and then dissolved with MilliQ (DNase-, RNase-free water; In vitrogen) was used as an RNA sample.
- ATCC No. BAA-308 ATCC No. BAA-308
- N6—T7primer (2. M) or N9-T7primer (2.5 M) was adjusted to 2.0: L calorie and MilliQ to a total volume of 10.0: L, and kept at 70 ° C for 5 minutes for denature. And kept at 4 ° C on ice.
- the enzymes and reagents described in Table 1 were added to each Denature mixture obtained in 1) above using the Superscript Choice System for cDNA Synthesis (Invitrogen). After that, RT reaction was performed at 37 ° C for 1 hour. After RT reaction, the enzyme was inactivated at 70 ° C for 10 minutes, and kept at 4 ° C for 3 minutes.
- Purify double-stranded cDNA solution (Purified cDNA solution; obtain 7 pieces) by dissolving in MilliQ (Invitrogen).
- Antisense aRNA was obtained by the IVT method using 8.0 L of the purified double-stranded cDNA solution obtained in 4) above. This IVT method was performed by adding the enzymes and reagents listed in Table 3 to the purified double-stranded cDNA solution (MEGAspript T7 Kit: Ambion) and then incubating at 37 ° C overnight.
- the amount of antisense aRNA amplified by the IVT method (IVT (+)) and the amount of RNA without IVT (IVT (—)) are stored in an absorptiometer (Ultrospec 3100 pro: Amersham Biosciences) Measured and calculated and shown in Table 4.
- IVT amplification there is no significant difference in IVT amplification ratio between N6—T7 primer and N9—T7 primer. Amplification of total RNA was observed. Although no particular results were shown, those using the same amount of total RNA before amplification showed almost the same amplification efficiency after IVT.
- the mRNA of htp35 gene encoding Porphvromonas gingivalis outer membrane protein was amplified. 2.0 g of total RNA extracted from Porphyromonas gingivalis W83 strain in mid-log phase was used as a sample. Using the Htp35 gene specific T7primer (2.5 M) described in SEQ ID NO: 3 in the sequence listing in which a T7 promoter region is added to a specific sequence of the to gene, the method described in Examples 2, 1) to 5) above. Amplification was performed by the IVT method.
- the sample (IVT (+)) amplified by the IVT method was confirmed to have a lower V and cycle rise than the unamplified sample (IVT (1)).
- IVT (-) was 2.
- OX 10 6 copies and IVT (+) was 9.1 X 10 7 copies.
- the amplification factor was calculated to be about 45, and it was confirmed that the prokaryotic RNA was amplified even when the T7 promoter region was added to the specific sequence of the htO35 gene.
- RNA amplification using a random primer with a promoter region of Example 1 enables RNA amplification of microgram order useful for microarray and Northern blot analysis, etc. from bacterial RNA of ng order. investigated.
- RNA solution was denatured at 70 ° C for 10 minutes and then kept on ice for 2 minutes o
- the double-stranded cDNA synthesis mix (ds cDNA synthesis mix) obtained in 2.3) above was purified using a column of QIAquick PCR Purification Kit (Qiagen). The purified double-stranded cDNA was dissolved twice with 50 ⁇ L of MilliQ.
- the MEGAspript T7 Kit (Ambion) was directly added to the double-stranded cDNA pellet obtained in 2.4) above, and the IVT was then added in the same manner as in Example 1 using the same procedure as in Example 1. Went the law.
- a method of synthesizing only the sense strand from aRNA (2) a method of synthesizing the senseZantisense strand simultaneously, or (3) a method of synthesizing only the antisense strand.
- Each strand was amplified and aRNA was synthesized.
- Method (1) As a method of synthesizing only the sense strand from RNA, N6—T7primer described in SEQ ID NO: 1 was added to antisense aRNA obtained by 1-cycle IVT method and RT reaction was performed. Only sense aRNA was obtained by strand cDNA synthesis and IVT method. The outline of the method is shown in Fig. 1.
- Method (2) In the method of simultaneously synthesizing the senseZantisense strand from RNA, N6—T7primer described in SEQ ID NO: 1 was added to antisense aRNA obtained by 1 cycle I VT method, and RT reaction was performed. The RNA in the form of a cocoon was decomposed and removed and purified. Subsequently, double-stranded cDNA was synthesized by adding a commercially available random primer with 6 N bonds, and senseZantisense aRNA was obtained by performing the IVT method. An overview of the method is shown in Figure 2.
- Enzymes and reagents were added to the Denature mixture obtained in 1.1) above using the Superscript Choice System for cDNA Synthesis (Invitrogen) to the composition shown in Table 9. Thereafter, it was incubated at 25 ° C for 10 minutes. To this, 1.1 was added Superscript II (Invitrogen) in the kit, and RT reaction was performed at 42 ° C for 1 hour. After RT reaction, it was incubated at 70 ° C for 10 minutes to inactivate the enzyme and kept at 4 ° C for 3 minutes.
- Double-stranded cDNA synthesis (ds cDNA Synthesis)
- the enzymes and reagents listed in Table 11 were added using the Amino Allyl transferase Amp ARNA Kit (Ambion) and MEGAscript T7 Kit (Ambion). After the addition, the IVT method was performed in the same manner as in Example 1. (1) Only the sense strand was synthesized by the method of synthesizing only the sense strand, (2) the senseZantisense strand was synthesized by the method of synthesizing the senseZantisense strand simultaneously, or (3) only the antisense strand was synthesized by the method of synthesizing only the antisense strand.
- IVT 435 sense / antisense 34, 936 ⁇ 7S52 80. 3 ⁇ 1 8. 1
- lOng of total RNA is finally reduced to about 16 ⁇ g by the method of amplifying only the sense of method (1) or the method of amplifying only the antisense of method (3).
- various transcriptome analyzes such as Northern plot analysis are possible with a small amount of prokaryotic RNA. It was considered.
- a global transcriptome analysis was performed using the Affymetrix GeneChip gene expression microarray, and the correlation of each amplified RNA sample was examined.
- GeneChip sense strand gene probes are spotted on the array, so the sample to be bound to the array must finally synthesize aRNA consisting only of the antisense strand, and streptavidin is added to the bound RNA sample. Since one fluorescent dye is fluorescent by indirect staining, it is necessary to label the sample with piotin that binds to streptavidin. Therefore, for preparation of samples, a thiotin-labeled antisense aRNA was synthesized.
- the IVT method with biotin labeling was performed during the second cycle of IVT, and was performed by adding Bio-11 CTP and Bio-16-UTP (Enzo) to the MEGAscript T7 Kit (Ambion) (Table 1). 13). Piotin labeling was performed by incubating at 37 ° C for 16 hours. Finally, 1.0 L of 2 UZ w L of DNase H was added and incubated at 37 ° C for 30 minutes to completely degrade the truncated cDNA.
- Each aRNA labeled with biotin in the above 1) was purified using a purification column in the Amino Allyl Message Amp aRNA Kit.
- the aRNA was dissolved by passing 50 L of MilliQ through the column twice.
- the purified IVT product was fragmented to bind to a short 25 mer gene probe on the GeneChip.
- aRNA 2-4 ⁇ g
- 10 L of 5x Fragmentation Buffer Affymetrix
- the total volume was adjusted to 50.
- O / z L with MilliQ By incubating this at 94 ° C for 35 minutes, the aRNA fragment was fragmented to a size of about 35 to 200 bp.
- E. coli total RNA as a sample, only a biotin-labeled antisense aRNA probe was synthesized by 1-cycle IVT method or 2-cycle IVT method, and this was synthesized into a GeneChi ⁇ array (E. coli Genome 2.0 Array; Affymetrix), and examined the correlation between the 1-cycle amplification and the GeneChip results for 2-cycle amplified samples.
- probes are usually synthesized by labeling biotin at the 3rd and 3rd ends of each fragment after synthesizing cDNA from total RNA using random primers.
- the IVT method with biotin labeling was performed by adding Bio-11-CTP and Bio-16-UTP (Enzo) to MEGAscript T7 Kit (Ambion) (Table 13) for 16 hours at 37 ° C. Then, 1.0 L of 2UZ L of DNase H was added and incubated at 37 ° C for 30 minutes to decompose the vertical cDNA. By purifying this, 21 ⁇ L of purified piotin-labeled antisense aRNA solution was obtained.
- the purified IVT product was fragmented from an aRNA sample in order to bind to a short 25-mer gene probe on the GeneChip.
- Each aRNA (2-4 g) was prepared by adding 10. L of 5x Fragmentation Buffer (Affymetrix) to a total volume of 50. MilliQ and incubating at 94 ° C for 5 minutes. The obtained aRNA fragment was fragmented to a size of about 35 to 200 bp.
- Add each reagent to make a hybridization cocktail, and then hybridize the hybridization cocktail with 80.0 ⁇ L and the chip at 45 ° C for 16 hours. It was. After washing the chip, staining with streptavidin-fluorescent (Phycoerythrin; Molecular Probes) label was performed. Furthermore, after the chip was washed again, the fluorescence intensity was measured with a scanner (Affymetrix).
- Fig. 7 shows a scatter plot of the variability between the two samples in each group using the 1-cycle IVT method and the 2-cycle IVT method. 2 cycle IVT compared to 1 cycle IVT method The method slightly increased the variation. This was presumed to be caused by two cycles of amplification from a small sample.
- the 2-cycle IVT method amplification shows some variation compared to the 1-cycle IVT method amplification
- the 2-cycle IVT method amplification shows a slight variation in the number of genes whose Flag information is displayed as “Present”.
- a decrease was observed, it was found that there was a high correlation between the analysis results obtained between the 1-cycle IVT method and the 2-cycle method.
- IVT amplification was performed using P. gineivalis. S. mutans and E. coli total RNA together with this primer, no significant difference in amplification efficiency was observed. It was suggested that a constant amplification efficiency can be expected regardless of the case.
- RNA sample (10.0 g) prepared in Example 6 10.0 L random hexamer (75.0 ng / ⁇ L; Invitrogen) and 2.0 L Diluted poly-A control (Affymetrix) was prepared and prepared with MilliQ to a total volume of 30.0 L. This was kept at 70 ° C for 10 minutes, further kept at 25 ° C for 10 minutes, and then placed on ice. To this, add the enzymes and reagents listed in Table 17 and hold at 25 ° C for 10 minutes, at 37 ° C for 60 minutes, at 42 ° C for 60 minutes, and further at 70 ° C for 10 minutes, and then at 4 ° C. Then, 20 ⁇ L of IN NaOH was added and kept at 65 ° C. for 30 minutes. After adding IN HC1 to this, MinElute PCR Purification Purification was performed using Kit (Qiagen).
- the product was eluted with 12 L of EB buffer included in the kit. 1 L of this was used for single-stranded cDNA concentration measurement.
- ss cDNA labeled sample
- the single-stranded cDNA 10 L (2-7 g) prepared in 1.1) was used as a sample. This was kept at 94 ° C for 10 minutes to denature and then kept on ice. To this, the enzymes and reagents listed in Table 18 were added and incubated at 37 ° C for 10 minutes, and then kept at 98 ° C for 10 minutes to obtain fragments.
- each reagent was added to prepare a hybridization cocktail, and the hybridization between the hybridization 80.0 L and the chip was performed at 45 ° C for 16 hours. I did it. After washing the chip, staining with streptavidin-fluorescent (Phycoerythrin; Molecular Probes) label was performed. Further, after the chip was washed again, the fluorescence intensity was measured with a scanner (Affymetrix).
- the gene expression pattern obtained by sample preparation according to the GeneChip manual is used to determine the gene expression in the 1-cycle IVT method or the gene expression in the 2-cycle IVT method obtained above. And the correlation between them was examined. As shown in Fig. 9, the correlation coefficient between the gene expression results in the manual method and the 1-cycle IVT method was significantly correlated with 0.75 (Parametric, two-tail, p ⁇ 0.01). The correlation coefficient between the gene expression results in the manual method and the 2-cycle IVT method is also statistically significant as 0.69 (Parametric, two-tail, p ⁇ 0.01) as shown in Fig. 10. Admitted.
- the number of gene expression confirmed by GeneChip analysis is 2,951 genes by manual method, 3,581 genes by 1-cycle IVT method, or There were 2,191 genes by the 2-cycle IVT method ( Figure 11). Of the 2,951 genes in the marine method, 78.6% overlapped with the 1-cycle IVT method, and 60.0% overlapped with the 2-cycle IVT method. In addition, there are 2,104 genes that overlap between the 1-cycle IVT method and the 2-cycle IVT method, and this number accounts for 58.8% of the 1-cycle IVT method and 96.0% of the 2-cycle IVT method. This result shows that most of the results obtained by the 2-cycle IVT method are included in the results obtained by the 1-cycle IVT method.
- the primer with the promoter region of the present invention can amplify RNA.
- the primer of the present invention By using the primer of the present invention to amplify microbial RNA obtained from microbial infection patients, and analyzing the obtained mRNA information by microarray, Northern blot, etc., the pathogenicity of pathogenic microorganisms is investigated and clinical diagnosis is performed. It can be used to select a prognosis treatment.
- FIG. 1 is a diagram showing an outline of a method for synthesizing only a sense strand from RNA (Example 4).
- FIG. 2 is a diagram showing an outline of a method for simultaneously synthesizing senseZantisense strands from RNA (Example 4).
- FIG. 3 shows an outline of a method for synthesizing only an antisense strand from RNA (Example 4).
- FIG. 4 is a diagram showing the fragment size of total RNA purified from Streptococcus mutans (Example 4).
- FIG. 5 shows the fragment size of aRNA synthesized by the 1-cycle IVT method (Example 4).
- FIG. 6 is a diagram showing the fragment size of aRNA synthesized by the 2-cycle IVT method (Example 4).
- FIG. 7 is a graph showing the variation between two samples in each group subjected to the 1-cycle IVT method and the 2-cycle IVT method (Example 6).
- FIG. 8 is a graph showing a correlation function of gene expression results in the 1-cycle IVT method and the 2-cycle IVT method (Example 6).
- FIG. 9 is a diagram showing the correlation coefficient between gene expression results by GeneChip method and 1-cycle IVT method (Example 7).
- FIG. 10 is a graph showing a correlation coefficient between gene expression results by GeneChip method and 2-cycle IVT method (Example 7).
- FIG. Ll A graph showing the number of genes determined to be expressed by the GeneChip method, the 1-cycle IVT method, and the 2-cycle IVT method (Example 7).
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Plant Pathology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05793619A EP1835026A4 (en) | 2004-10-14 | 2005-10-14 | PRIMER WITH PROMOTIVE AREA ADDED TO THIS |
JP2006540984A JPWO2006041159A1 (ja) | 2004-10-14 | 2005-10-14 | プロモーター領域を付加したプライマー |
US11/665,156 US20080096198A1 (en) | 2004-10-14 | 2005-10-14 | Primer Having Promoter Region Added Thereto |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004299976 | 2004-10-14 | ||
JP2004-299976 | 2004-10-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006041159A1 true WO2006041159A1 (ja) | 2006-04-20 |
Family
ID=36148445
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/018960 WO2006041159A1 (ja) | 2004-10-14 | 2005-10-14 | プロモーター領域を付加したプライマー |
Country Status (4)
Country | Link |
---|---|
US (1) | US20080096198A1 (ja) |
EP (1) | EP1835026A4 (ja) |
JP (1) | JPWO2006041159A1 (ja) |
WO (1) | WO2006041159A1 (ja) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003079667A1 (en) * | 2002-03-15 | 2003-09-25 | Arcturus Bioscience, Inc. | Improved nucleic acid amplification |
WO2004033669A2 (en) * | 2002-10-11 | 2004-04-22 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of | Methods of manipulating nucleic acids |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6582906B1 (en) * | 1999-04-05 | 2003-06-24 | Affymetrix, Inc. | Proportional amplification of nucleic acids |
WO2004061126A2 (en) * | 2002-03-25 | 2004-07-22 | Datascope Investment Corp. | Nucleic acid hybridization assay using bridging sequence |
WO2002044399A2 (en) * | 2000-11-28 | 2002-06-06 | Rosetta Inpharmatics, Inc. | In vitro transcription method for rna amplification |
US6794141B2 (en) * | 2000-12-22 | 2004-09-21 | Arcturus Bioscience, Inc. | Nucleic acid amplification |
EP1451346A2 (en) * | 2001-08-16 | 2004-09-01 | Curagen Corporation | Method of labelling crnas for probing oligo-based microarrays |
-
2005
- 2005-10-14 US US11/665,156 patent/US20080096198A1/en not_active Abandoned
- 2005-10-14 WO PCT/JP2005/018960 patent/WO2006041159A1/ja active Application Filing
- 2005-10-14 JP JP2006540984A patent/JPWO2006041159A1/ja active Pending
- 2005-10-14 EP EP05793619A patent/EP1835026A4/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003079667A1 (en) * | 2002-03-15 | 2003-09-25 | Arcturus Bioscience, Inc. | Improved nucleic acid amplification |
WO2004033669A2 (en) * | 2002-10-11 | 2004-04-22 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of | Methods of manipulating nucleic acids |
Non-Patent Citations (4)
Title |
---|
DE L ET AL: "Identification of vaccine-related polioviruses by hybridization with specific RNA probes.", J CLIN MICROBIOL., vol. 33, no. 3, March 1995 (1995-03-01), pages 562 - 571, XP002995057 * |
PHILLIPS J AND EBERWINE J H.: "Antisense RNA Amplification: A Linear Amplification Method for Analyzing the mRNA Population from Single Living Cells.", METHODS: A COMPARISON TO METHODS IN ENXYMOLOGY., vol. 10, no. 3, 1996, pages 283 - 288, XP002248904 * |
See also references of EP1835026A4 * |
ZHU Y Y ET AL: "Reverse transcriptase template switching: a SMART approach for full-length cDNA library construction.", BIOTECHNIQUES., vol. 30, no. 4, April 2001 (2001-04-01), pages 892 - 897, XP001121210 * |
Also Published As
Publication number | Publication date |
---|---|
US20080096198A1 (en) | 2008-04-24 |
JPWO2006041159A1 (ja) | 2008-08-07 |
EP1835026A4 (en) | 2009-11-04 |
EP1835026A1 (en) | 2007-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113166797B (zh) | 基于核酸酶的rna耗尽 | |
JP7504854B2 (ja) | 個別的エピゲノミクスのための天然クロマチンへの転移 | |
EP1786930B1 (en) | Methods for tailing and amplifying rna | |
EP2816111B1 (en) | Methods, compositions, and kits for generating rRNA-depleted samples or isolating rRNA from samples | |
Ginsberg | RNA amplification strategies for small sample populations | |
US20030108930A1 (en) | Method of evaluating drug efficacy and toxicity | |
Livesey | Strategies for microarray analysis of limiting amounts of RNA | |
JP2007506439A (ja) | 少量の核酸を合成する方法 | |
JP2002262882A (ja) | Rnaの増幅法 | |
JP2023547394A (ja) | オリゴハイブリダイゼーションおよびpcrベースの増幅による核酸検出方法 | |
Skvortsov et al. | A review of the transcriptome analysis of bacterial pathogens in vivo: Problems and solutions | |
US20030022318A1 (en) | Method for thermocycling amplification of nucleic acid sequences and the generation of related peptides thereof | |
EP1275738A1 (en) | Method for random cDNA synthesis and amplification | |
JPWO2005118791A1 (ja) | 微量試料を用いる網羅的遺伝子発現プロフィール解析法 | |
JP2004194583A (ja) | リボゾームrnaを標的とした抗酸菌の検出法 | |
US20030113754A1 (en) | Method for random cDNA amplification | |
CN113012762A (zh) | 基于分子分类器的样本分类系统、试剂盒、方法及应用 | |
WO2006041159A1 (ja) | プロモーター領域を付加したプライマー | |
Duftner et al. | Efficacy of RNA amplification is dependent on sequence characteristics: implications for gene expression profiling using a cDNA microarray | |
JP2004532034A (ja) | 遺伝子発現分析システムでコントロールとして使用するための人工遺伝子のデザイン | |
US20120077196A9 (en) | Universal method for selective amplification of mRNAs | |
WO2011158784A1 (ja) | 大規模並列核酸分析方法 | |
Lawson et al. | Amplification of sense-stranded prokaryotic RNA | |
US20020110827A1 (en) | Quantitative mRNA amplification | |
EP1371726A1 (en) | Method for amplifying RNA |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006540984 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005793619 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11665156 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2005793619 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11665156 Country of ref document: US |